Cargando…
Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
Osteosarcoma (OS) and Ewing sarcoma (ES) are the two most common types of primary bone cancer that predominantly affect the young. Despite aggressive multimodal treatment, survival has not improved significantly over the past four decades. Clinical efficacy has historically been observed for some mo...
Autores principales: | Fleuren, Emmy D. G., Vlenterie, Myrella, van der Graaf, Winette T. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040783/ https://www.ncbi.nlm.nih.gov/pubmed/36994209 http://dx.doi.org/10.3389/fonc.2023.1013359 |
Ejemplares similares
-
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
por: Fleuren, Emmy D.G., et al.
Publicado: (2014) -
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016) -
Age as an independent prognostic factor for survival of localised synovial sarcoma patients
por: Vlenterie, Myrella, et al.
Publicado: (2015) -
Systemic Treatment for Adults with Synovial Sarcoma
por: Desar, Ingrid M. E., et al.
Publicado: (2018) -
Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma
por: van Erp, Anke E. M., et al.
Publicado: (2022)